Navigation Links
Zevacor Molecular Awards IBA Contract to Build Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
Date:11/4/2013

INDIANAPOLIS, Nov. 4, 2013 /PRNewswire/ -- Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A., (IBA).

The purchase of IBA's Cyclone 70 is the first of several investments Zevacor is making to secure the future of nuclear medicine and molecular imaging. The 70 MeV Cyclotron is expected to be operational in the fall of 2016 and will help to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses.

In addition to the cyclotron, Zevacor will also invest in significant infrastructure to create a new, state of the art manufacturing facility to house the Cyclone 70 as well as other cyclotrons and manufacturing equipment. A location is expected to be determined by the end of 2013.

"This is just the beginning," said John Zehner, Executive Vice President and Chief Operating Officer, Zevacor Molecular. "With strategic investments like the purchase of the Cyclone 70, Zevacor and our partners will help hospitals improve the diagnosis and treatment of cancer, cardiovascular disease and other critical illnesses. Our goal is to support the current needs of the nuclear medicine and molecular imaging community and assist in the growth and development of new diagnostics and therapeutics."

The main focus of the first 70 MeV Cyclotron will be the commercial manufacture of Strontium 82 to ensure ample, stable United States based supply of Strontium 82/Rubidium 82 generators for use in the diagnosis of cardiovascular disease.  This important radiotracer has no current commercial supplier, and only has United States and foreign based supply from national labs.

Although the primary focus is the manufacture of Strontium 82, the Cyclone 70 is capable of producing a wide variety of other radionuclides for both research and clinical applications. 

"We are delighted that Zevacor Molecular selected IBA to install the first commercial 70 MeV Cyclotron dedicated to the production of radiopharmaceuticals in the United States," said Olivier Legrain, Chief Executive Officer, IBA. "We are honored to partner with Zevacor Molecular and participate in their mission to help advance the care of patients through the provision of advanced diagnostic agents."

About Zevacor Molecular
Zevacor Molecular was established in 2012.  Their efforts come at a time when there is little certainty of supply in the market for medical isotopes. The 70 MeV will have the ability to supply patients with medically necessary isotopes used for diagnostic imaging and therapies within oncology, neurology and cardiology. This also opens up several research isotopes currently not widely available in the United States. More information can be found at www.zevacor.com

About IBA
Ion Beam Applications S.A., (IBA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment.  IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions.  IBA also focuses on the development and supply of dosimetry solutions for quality assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications. More information can be found at www.iba-worldwide.com


'/>"/>
SOURCE Zevacor Molecular
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zevacor Molecular to Open Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
2. PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors
3. LUMINEX CORPORATION TO HOST INVESTOR EVENT AT ASSOCIATION FOR MOLECULAR PATHOLOGY ANNUAL MEETING
4. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
5. MR Solutions to Launch Two World Firsts in Pre Clinical Scanning at the World Molecular Imaging Conference in Savannah This Week - a Combined 3T, Cryogen Free MRI/PET and a 3T MRI/SPECT
6. Technology Innovation Provides Catalyst for Scientific Breakthroughs in Precision Medicine at World Molecular Imaging Congress
7. World Molecular Imaging Congress to Feature Scientific Breakthroughs in Molecular Multimodal Imaging Essential to Precision Medicine
8. Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community Oncologists
9. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
10. Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporations xMAP Technology
11. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
Breaking Medicine News(10 mins):